We assessed the cross-presentation ability of DCs using the NY-ESO-1 specific CD8+ CTL clones generated by directly sorting HLA-A2 NY-ESO-1 157−165 tetramers from a melanoma patient (31, 55). This evidence concerns the gene CD8A and melanoma.